Share on StockTwits

Novabay Pharmaceutic (NYSE:NBY) Director Mark M. Sieczkarek acquired 4,800 shares of the stock in a transaction dated Wednesday, June 4th. The shares were purchased at an average cost of $0.89 per share, with a total value of $4,272.00. Following the completion of the acquisition, the director now directly owns 29,800 shares in the company, valued at approximately $26,522. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Edison Investment Research reiterated a “positive” rating on shares of Novabay Pharmaceutic in a research note on Friday, March 28th.

Novabay Pharmaceutic (NYSE:NBY) traded down 2.22% during mid-day trading on Thursday, hitting $0.88. 92,716 shares of the company’s stock traded hands. Novabay Pharmaceutic has a 52-week low of $0.76 and a 52-week high of $2.03. The stock has a 50-day moving average of $0.94 and a 200-day moving average of $1.16. The company’s market cap is $44.7 million.

Novabay Pharmaceutic (NYSE:NBY) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, analysts predict that Novabay Pharmaceutic will post $-0.34 earnings per share for the current fiscal year.

NovaBay Pharmaceuticals, Inc (NYSE:NBY) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.